Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit …
Post
-
-
FiberSense plans CGM’s commercial readiness following CE mark
FiberSense has obtained a CE mark for its continuous glucose monitoring (CGM) system, setting the stage for the medical device’s …
-
Podcast: What the AHA-ASA’s updated guidelines mean for acute ischemic stroke care
In January 2026, the American Heart and American Stroke Association (AHA/ASA) issued new care guidelines for acute ischemic stroke (AIS) …
-
Sonire Therapeutics awarded $13m from Japanese government-backed innovation agency
The government of Japan has inducted Sonire Therapeutics’ Japan-based group into an innovation programme, along with equipping the company with …
-
BCAL Diagnostics develops blood test to evaluate breast cancer
Australian healthcare company BCAL Diagnostics is developing the BREASTEST Monitor blood test intended to assist in evaluating women for local …
-
Podcast: What the AHA-ASA’s updated guidelines mean for acute ischemic stroke care
In January 2026, the American Heart and American Stroke Association (AHA/ASA) issued new care guidelines for acute ischemic stroke (AIS) …
-
Sonire Therapeutics awarded $13m from Japanese government-backed innovation agency
The government of Japan has inducted Sonire Therapeutics’ Japan-based group into an innovation programme, along with equipping the company with …
-
BCAL Diagnostics develops blood test to evaluate breast cancer
Australian healthcare company BCAL Diagnostics is developing the BREASTEST Monitor blood test intended to assist in evaluating women for local …
-
AngioDynamics secures FDA approval for RELIEF study of NanoKnife
AngioDynamics has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption application to begin …
-
Italy’s WISE raises $34.8m in Series D to advance spinal cord stimulator development
WISE has raised €30m ($34.8m) to advance the development of its spinal cord stimulation (SCS) device for chronic pain treatment. The …
-
NHS Confed 2026: what drives successful AI implementation in the NHS?
The UK’s Labour government has ambitious plans to transform the country’s National Health Service (NHS) into one that is more …
-
Memphasys and Monash IVF sign national supply deal for Felix system
Australian-based Memphasys and Monash IVF Group have finalised a 12-month exclusive national supply agreement for the Felix automated sperm selection …
-
LivaNova’s programming algorithm boosts response rates in sleep apnoea patients
New data from LivaNova has demonstrated the clinical benefit of its programming algorithm in patients with obstructive sleep apnoea (OSA). Trial …
-
Distalmotion secures second FDA gynaecology clearance for DEXTER system
Swiss medical device company Distalmotion has secured the US Food and Drug Administration (FDA) 510(k) clearance for its DEXTER robotic …
-
Penumbra’s Thunderbolt approval poised to accelerate neuro thrombectomy innovation
Penumbra has secured FDA approval for its Thunderbolt system, the first device to offer computer-assisted vacuum therapy (CAVT) for stroke …
